首页 > 最新文献

Annals of the Child Neurology Society最新文献

英文 中文
Under-recognition of leg dystonia in people with cerebral palsy 脑瘫患者下肢肌张力障碍的识别不足
Pub Date : 2023-04-05 DOI: 10.1002/cns3.20018
Bhooma Aravamuthan, Toni S. Pearson, Keerthana Chintalapati, Keisuke Ueda

Objective

To determine the rates of clinical under-documentation of leg dystonia in people with cerebral palsy (CP).

Methods

In this prospective cohort study, we identified independently ambulatory people age 10–20 years with CP-associated spasticity seen in a tertiary care CP center between 1/1/20 and 11/4/21. Three pediatric movement disorders specialists assessed gait videos from these visits for leg dystonia using the Global Dystonia Rating Scale. We compared the gold standard expert consensus assessment for each patient with the clinical documentation of dystonia during a contemporaneous CP center clinic visit and also with dystonia documentation longitudinally in their medical record.

Results

Of 116 people with CP-associated spasticity assessed in this study, 70 were found to have leg dystonia in their gait videos. Only 13% of these 70 individuals (n = 9/70) had leg dystonia documented in their contemporaneous CP center clinic visit, even though they were assessed during this visit by clinicians well trained in CP and dystonia assessment. Even with repeated assessment, only 54% (n = 38/70) of these individuals had leg dystonia documented in their medical record.

Conclusions

Leg dystonia is clinically under-documented in people with CP-associated spasticity, even when these people are evaluated by well-trained clinicians. Longitudinal evaluation and vigilance for leg dystonia is critical to address this diagnostic gap.

目的:确定脑瘫(CP)患者下肢肌张力障碍的临床记录率。
{"title":"Under-recognition of leg dystonia in people with cerebral palsy","authors":"Bhooma Aravamuthan,&nbsp;Toni S. Pearson,&nbsp;Keerthana Chintalapati,&nbsp;Keisuke Ueda","doi":"10.1002/cns3.20018","DOIUrl":"10.1002/cns3.20018","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To determine the rates of clinical under-documentation of leg dystonia in people with cerebral palsy (CP).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this prospective cohort study, we identified independently ambulatory people age 10–20 years with CP-associated spasticity seen in a tertiary care CP center between 1/1/20 and 11/4/21. Three pediatric movement disorders specialists assessed gait videos from these visits for leg dystonia using the Global Dystonia Rating Scale. We compared the gold standard expert consensus assessment for each patient with the clinical documentation of dystonia during a contemporaneous CP center clinic visit and also with dystonia documentation longitudinally in their medical record.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 116 people with CP-associated spasticity assessed in this study, 70 were found to have leg dystonia in their gait videos. Only 13% of these 70 individuals (<i>n</i> = 9/70) had leg dystonia documented in their contemporaneous CP center clinic visit, even though they were assessed during this visit by clinicians well trained in CP and dystonia assessment. Even with repeated assessment, only 54% (<i>n</i> = 38/70) of these individuals had leg dystonia documented in their medical record.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Leg dystonia is clinically under-documented in people with CP-associated spasticity, even when these people are evaluated by well-trained clinicians. Longitudinal evaluation and vigilance for leg dystonia is critical to address this diagnostic gap.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72232,"journal":{"name":"Annals of the Child Neurology Society","volume":"1 2","pages":"162-167"},"PeriodicalIF":0.0,"publicationDate":"2023-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cns3.20018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46079015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
SIGnature Libraries: A roadmap for the formation of special interest group libraries SIGnature图书馆:形成特殊兴趣群体图书馆的路线图。
Pub Date : 2023-03-23 DOI: 10.1002/cns3.20021
Young-Min Kim, Eric M. Chin, Michael Fahey, Rose Gelineau-Morel, Kate Himmelmann, Jennifer O'Malley, Maryam Oskoui, Bruce Shapiro, Michael Shevell, Jenny L. Wilson, Max Wiznitzer, the Child Neurology Society Cerebral Palsy Special Interest Group Consortium, Bhooma Aravamuthan

Objective

“SIGnature Libraries” channel the dynamism of academic society-based special interest groups (SIG) to systematically identify and provide user-oriented access to essential literature for a subspecialty field in a manner that keeps pace with the field's continuing evolution. The libraries include literature beyond clinical trial data to encompass historical context, diagnostic conceptualization, and community organization materials to foster a holistic understanding of how neurologic conditions affect individuals, their community, and their lived experience.

Methods

Utilizing a modified-Delphi approach, Child Neurology Society's Cerebral Palsy (CP) SIG (n = 75) administered two rounds of literature submissions and ratings. A final review by an 11-member international advisory group determined threshold ratings for resource inclusion and the library's final structure.

Results

Seventy-nine articles were submitted for the first Delphi round and 22 articles for the second Delphi round. Survey response rates among SIG members were 29/75 for the first round and 24/75 for the second round. The advisory board added additional articles in the final review process in view of the overall project goal. A total of 60 articles were included in the final library, and articles were divided into seven sections and stratified by rating scores. A process for ongoing revisions of the library was determined. The library will be published on the Child Neurology Society website and made publicly accessible.

Conclusions

The CP SIGnature Library offers learners an unprecedented resource that provides equitable access to latest consensus guidelines, existing seminal datasets, up-to-date review articles, and other patient care tools. A distinctive feature of the library is its intentional large scope and depth, presented in a stratified fashion relative to the consensus-determined importance of each article. Learners can efficiently navigate the library based on individual interests and goals, and the library can be used as core curriculum for CP education.

目标:“SIGnature图书馆”引导基于学术社会的特殊利益团体(SIG)的活力,以与该领域的持续发展同步的方式,系统地识别并提供面向用户的子专业领域基本文献访问。这些图书馆包括临床试验数据之外的文献,包括历史背景、诊断概念和社区组织材料,以促进对神经系统状况如何影响个人、他们的社区和他们的生活经历的全面理解。方法:采用改良的德尔菲方法,儿童神经病学学会脑瘫SIG(n=75)进行两轮文献提交和评分。一个由11名成员组成的国际咨询小组进行了最后审查,确定了纳入资源的门槛评级和图书馆的最终结构。结果:第一轮Delphi共提交79篇文章,第二轮Delphi提交22篇文章。SIG成员的调查回复率第一轮为29/75,第二轮为24/75。鉴于项目的总体目标,咨询委员会在最后审查过程中增加了其他条款。最终图书馆共收录了60篇文章,文章分为七个部分,并根据评分进行分层。已确定对图书馆进行持续修订的程序。该图书馆将在儿童神经学会网站上公布,并向公众开放。结论:CP SIGnature图书馆为学习者提供了前所未有的资源,可以公平地访问最新的共识指南、现有的开创性数据集、最新的综述文章和其他患者护理工具。图书馆的一个显著特点是其有意的大范围和深度,相对于每一篇文章的一致决定的重要性,以分层的方式呈现。学习者可以根据个人兴趣和目标有效地浏览图书馆,图书馆可以作为CP教育的核心课程。
{"title":"SIGnature Libraries: A roadmap for the formation of special interest group libraries","authors":"Young-Min Kim,&nbsp;Eric M. Chin,&nbsp;Michael Fahey,&nbsp;Rose Gelineau-Morel,&nbsp;Kate Himmelmann,&nbsp;Jennifer O'Malley,&nbsp;Maryam Oskoui,&nbsp;Bruce Shapiro,&nbsp;Michael Shevell,&nbsp;Jenny L. Wilson,&nbsp;Max Wiznitzer,&nbsp;the Child Neurology Society Cerebral Palsy Special Interest Group Consortium,&nbsp;Bhooma Aravamuthan","doi":"10.1002/cns3.20021","DOIUrl":"10.1002/cns3.20021","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>“SIGnature Libraries” channel the dynamism of academic society-based special interest groups (SIG) to systematically identify and provide user-oriented access to essential literature for a subspecialty field in a manner that keeps pace with the field's continuing evolution. The libraries include literature beyond clinical trial data to encompass historical context, diagnostic conceptualization, and community organization materials to foster a holistic understanding of how neurologic conditions affect individuals, their community, and their lived experience.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Utilizing a modified-Delphi approach, Child Neurology Society's Cerebral Palsy (CP) SIG (<i>n</i> = 75) administered two rounds of literature submissions and ratings. A final review by an 11-member international advisory group determined threshold ratings for resource inclusion and the library's final structure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Seventy-nine articles were submitted for the first Delphi round and 22 articles for the second Delphi round. Survey response rates among SIG members were 29/75 for the first round and 24/75 for the second round. The advisory board added additional articles in the final review process in view of the overall project goal. A total of 60 articles were included in the final library, and articles were divided into seven sections and stratified by rating scores. A process for ongoing revisions of the library was determined. The library will be published on the Child Neurology Society website and made publicly accessible.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The CP SIGnature Library offers learners an unprecedented resource that provides equitable access to latest consensus guidelines, existing seminal datasets, up-to-date review articles, and other patient care tools. A distinctive feature of the library is its intentional large scope and depth, presented in a stratified fashion relative to the consensus-determined importance of each article. Learners can efficiently navigate the library based on individual interests and goals, and the library can be used as core curriculum for CP education.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72232,"journal":{"name":"Annals of the Child Neurology Society","volume":"1 3","pages":"218-227"},"PeriodicalIF":0.0,"publicationDate":"2023-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fd/48/nihms-1902114.PMC10550070.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41164632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Meningitis caused by the varicella vaccine virus in 17 immunized children and adolescents from the United States, Europe, and Japan 由水痘疫苗病毒引起的脑膜炎在美国、欧洲和日本的17名免疫儿童和青少年中发生
Pub Date : 2023-03-22 DOI: 10.1002/cns3.20020
Charles Grose, Daniel J. Bonthius

The varicella vaccination program has an excellent safety record. The vaccine virus, like its wild-type counterpart, can enter latency and later reactivate as herpes zoster. A lesser known but serious adverse event following reactivation is varicella vaccine meningitis. We investigate that adverse event. We performed a literature search using the PubMed and Google Scholar search engines to locate all published cases of varicella vaccine meningitis. We continued the search through January 2023. We found 17 cases of varicella vaccine meningitis. The first case was published in 2003, and the last case was published in 2023. The children lived in the United States, Greece, Germany, Switzerland, and Japan. Among the 17 cases, 14 were immunocompetent; nine of the 17 were adolescents. One potential risk factor was the administration of corticosteroids three to four weeks before the onset of meningitis. Varicella vaccine meningitis is a rare but one of the more serious adverse events that occurs several years following varicella vaccination. In immunocompetent children, this complication is treatable with a single course of intravenous acyclovir after hospitalization.

水痘疫苗接种计划有着良好的安全记录。疫苗病毒和野生型病毒一样,可以进入潜伏期,然后重新激活为带状疱疹。水痘疫苗再激活后的一个鲜为人知但严重的不良事件是脑膜炎。我们对该不良事件进行调查。我们使用PubMed和Google Scholar搜索引擎进行了文献搜索,以查找所有已发表的水痘疫苗脑膜炎病例。我们继续搜索到2023年1月。我们发现17例水痘疫苗脑膜炎。第一个病例于2003年公布,最后一个病例于2023年公布。孩子们生活在美国、希腊、德国、瑞士和日本。17例中,14例具有免疫活性;17人中有9人是青少年。一个潜在的风险因素是在脑膜炎发作前三到四周服用皮质类固醇。水痘疫苗脑膜炎是一种罕见但更严重的不良事件,发生在水痘疫苗接种几年后。在免疫功能良好的儿童中,这种并发症可以在住院后通过单疗程静脉注射阿昔洛韦来治疗。
{"title":"Meningitis caused by the varicella vaccine virus in 17 immunized children and adolescents from the United States, Europe, and Japan","authors":"Charles Grose,&nbsp;Daniel J. Bonthius","doi":"10.1002/cns3.20020","DOIUrl":"10.1002/cns3.20020","url":null,"abstract":"<p>The varicella vaccination program has an excellent safety record. The vaccine virus, like its wild-type counterpart, can enter latency and later reactivate as herpes zoster. A lesser known but serious adverse event following reactivation is varicella vaccine meningitis. We investigate that adverse event. We performed a literature search using the PubMed and Google Scholar search engines to locate all published cases of varicella vaccine meningitis. We continued the search through January 2023. We found 17 cases of varicella vaccine meningitis. The first case was published in 2003, and the last case was published in 2023. The children lived in the United States, Greece, Germany, Switzerland, and Japan. Among the 17 cases, 14 were immunocompetent; nine of the 17 were adolescents. One potential risk factor was the administration of corticosteroids three to four weeks before the onset of meningitis. Varicella vaccine meningitis is a rare but one of the more serious adverse events that occurs several years following varicella vaccination. In immunocompetent children, this complication is treatable with a single course of intravenous acyclovir after hospitalization.</p>","PeriodicalId":72232,"journal":{"name":"Annals of the Child Neurology Society","volume":"1 2","pages":"96-101"},"PeriodicalIF":0.0,"publicationDate":"2023-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cns3.20020","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45953653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Pyridoxine-dependent epilepsy: Current perspectives and questions for future research 吡哆醇依赖性癫痫的研究现状与问题
Pub Date : 2023-03-07 DOI: 10.1002/cns3.20016
Curtis R. Coughlin  II, Sidney M. Gospe  Jr.
Pyridoxine‐dependent epilepsy (PDE) was historically defined by a dramatic clinical response to a trial of pyridoxine and the re‐emergence of seizures after withdrawal of pyridoxine. Research conducted over the last seven decades has revealed that the phenotype of PDE results from multiple genetic disorders, and the most common disorder, PDE‐ALDH7A1, is caused by a deficiency of an enzyme involved in lysine metabolism. PDE‐ALDH7A1 is characterized by more than epilepsy, as many patients have abnormalities of brain development, and most patients have intellectual and developmental disability. Treatment aimed at the underlying metabolic defect, in addition to pyridoxine supplementation, has improved clinical outcomes. Recently discovered biomarkers and genetic testing allow for the diagnosis of PDE‐ALDH7A1 without the need of a pyridoxine trial and hold the promise for newborn screening. Despite these many advances, PDE‐ALDH7A1 remains a clinical and biochemical conundrum. The increasing use of model systems and an international collaboration of clinician‐scientists are among the reasons to be optimistic that these questions will be answered in the near future and that the clinical outcomes and quality of life will continue to improve for patients with PDE‐ALDH7A1.
吡哆醇依赖性癫痫(PDE)在历史上被定义为对吡哆醇试验的显著临床反应和停药后癫痫发作的再次出现。在过去70年中进行的研究表明,PDE的表型是由多种遗传疾病引起的,最常见的疾病PDE-ALDH7A1是由赖氨酸代谢相关酶缺乏引起的。PDE-ALDH7A1的特征不仅仅是癫痫,因为许多患者都有大脑发育异常,大多数患者都有智力和发育障碍。针对潜在代谢缺陷的治疗,除了补充吡哆醇外,还改善了临床结果。最近发现的生物标志物和基因检测允许在不需要吡哆醇试验的情况下诊断PDE-ALDH7A1,并有望用于新生儿筛查。尽管取得了许多进展,PDE-ALDH7A1仍然是一个临床和生化难题。模型系统的日益使用和临床医生科学家的国际合作是乐观的原因之一,这些问题将在不久的将来得到回答,PDE-ALDH7A1患者的临床结果和生活质量将继续改善。
{"title":"Pyridoxine-dependent epilepsy: Current perspectives and questions for future research","authors":"Curtis R. Coughlin  II,&nbsp;Sidney M. Gospe  Jr.","doi":"10.1002/cns3.20016","DOIUrl":"https://doi.org/10.1002/cns3.20016","url":null,"abstract":"Pyridoxine‐dependent epilepsy (PDE) was historically defined by a dramatic clinical response to a trial of pyridoxine and the re‐emergence of seizures after withdrawal of pyridoxine. Research conducted over the last seven decades has revealed that the phenotype of PDE results from multiple genetic disorders, and the most common disorder, PDE‐ALDH7A1, is caused by a deficiency of an enzyme involved in lysine metabolism. PDE‐ALDH7A1 is characterized by more than epilepsy, as many patients have abnormalities of brain development, and most patients have intellectual and developmental disability. Treatment aimed at the underlying metabolic defect, in addition to pyridoxine supplementation, has improved clinical outcomes. Recently discovered biomarkers and genetic testing allow for the diagnosis of PDE‐ALDH7A1 without the need of a pyridoxine trial and hold the promise for newborn screening. Despite these many advances, PDE‐ALDH7A1 remains a clinical and biochemical conundrum. The increasing use of model systems and an international collaboration of clinician‐scientists are among the reasons to be optimistic that these questions will be answered in the near future and that the clinical outcomes and quality of life will continue to improve for patients with PDE‐ALDH7A1.","PeriodicalId":72232,"journal":{"name":"Annals of the Child Neurology Society","volume":"1 1","pages":"24-37"},"PeriodicalIF":0.0,"publicationDate":"2023-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cns3.20016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50137413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Neuroradiological findings in children with subdural hematoma and suspected abusive head trauma 儿童硬膜下血肿和疑似虐待性头部创伤的神经放射学表现
Pub Date : 2023-03-03 DOI: 10.1002/cns3.3
Sverre Morten Zahl, Jacob Andersson, Knut Wester, Johan Wikström
Abusive head trauma (AHT) is often suspected in infants with subdural hematoma (SDH). Other neuroradiological findings have also been reported in assumed AHT, such as hypoxic–ischemic injury (HII), cortical vein thrombosis, and subarachnoid hemorrhage. The purpose of this study was to investigate neuroradiological and clinical findings in cases of suspected AHT.
虐待性头部创伤(AHT)常被怀疑在婴儿硬膜下血肿(SDH)。在假定的AHT中也报道了其他神经放射学表现,如缺氧缺血性损伤(HII)、皮质静脉血栓形成和蛛网膜下腔出血。本研究的目的是调查疑似AHT病例的神经放射学和临床表现。
{"title":"Neuroradiological findings in children with subdural hematoma and suspected abusive head trauma","authors":"Sverre Morten Zahl,&nbsp;Jacob Andersson,&nbsp;Knut Wester,&nbsp;Johan Wikström","doi":"10.1002/cns3.3","DOIUrl":"10.1002/cns3.3","url":null,"abstract":"Abusive head trauma (AHT) is often suspected in infants with subdural hematoma (SDH). Other neuroradiological findings have also been reported in assumed AHT, such as hypoxic–ischemic injury (HII), cortical vein thrombosis, and subarachnoid hemorrhage. The purpose of this study was to investigate neuroradiological and clinical findings in cases of suspected AHT.","PeriodicalId":72232,"journal":{"name":"Annals of the Child Neurology Society","volume":"1 1","pages":"44-52"},"PeriodicalIF":0.0,"publicationDate":"2023-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cns3.3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42870960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Burden of illness in aromatic l-amino acid decarboxylase deficiency 芳香族l-氨基酸脱羧酶缺乏症的疾病负担
Pub Date : 2023-02-16 DOI: 10.1002/cns3.20010
Melissa L. DiBacco, Jordan Hinahara, Thomas F. Goss, Phillip L. Pearl

Objectives

Deficiency of aromatic l-amino acid decarboxylase (AADC), a key enzyme in monoamine synthesis, is an ultrarare disorder of monoamine synthesis estimated to affect fewer than 50 patients in the United States, although rates of misdiagnosis may be high. In its severe form, this congenital hypodopaminergic state results in profound hypotonia, developmental impairment, oculogyric crises, dystonia, dysautonomia, hypoglycemia, and premature death. The present study assesses the burden of illness for patients and caregivers by assessment of medical resource utilization (MRU) and quality of life (QOL) measures to enable future health technology assessment activities for emerging therapeutic options.

Methods

Data from patients’ medical records from the prior two years were examined to estimate burden in terms of direct costs; indirect care burden (including caregiver impact on sleep, health, and vocational opportunities) and QOL were also assessed using the BURQOL-RD, AQoL-6, and Visual Analogue Scale questionnaires.

Results

Data were available for five US cases (three males, two females; age, 2–24 years, median, 5 years). MRU ranged from $6162.73 to $49 043.94 annually per patient. Although the proportion of costs (inpatient and outpatient visits, labs/tests, drugs, devices/durable medical equipment, and speech/physical therapy) varied greatly, the average annual direct cost of healthcare was approximately $25 000. Caregivers described profound care burden and QOL effects, with an average indirect care burden cost assessment of nearly $43 000 yearly. The mean economic burden of AADC deficiency per year was estimated at $68 000.

Conclusion

MRU and QOL varied considerably by patient. This is attributable to the disease's variable phenotypic severity and differing patient needs. Frequent contact with the healthcare system, however, is a constant for patients with AADC deficiency and their caregivers. Quantifying MRU and QOL for rare genetic diseases is critical for assessing the value of emerging targeted therapies.

芳香族l-氨基酸脱羧酶(AADC)是单胺合成的关键酶,其缺乏是一种极为罕见的单胺合成障碍,估计在美国影响的患者不到50人,尽管误诊率可能很高。在严重的情况下,这种先天性低多巴胺能状态会导致严重的肌张力减退、发育障碍、眼肌危象、肌张力障碍、自主神经功能障碍、低血糖和过早死亡。本研究通过评估医疗资源利用率(MRU)和生活质量(QOL)指标来评估患者和护理人员的疾病负担,以使未来的卫生技术评估活动能够用于新的治疗方案。
{"title":"Burden of illness in aromatic l-amino acid decarboxylase deficiency","authors":"Melissa L. DiBacco,&nbsp;Jordan Hinahara,&nbsp;Thomas F. Goss,&nbsp;Phillip L. Pearl","doi":"10.1002/cns3.20010","DOIUrl":"10.1002/cns3.20010","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Deficiency of aromatic <span>l</span>-amino acid decarboxylase (AADC), a key enzyme in monoamine synthesis, is an ultrarare disorder of monoamine synthesis estimated to affect fewer than 50 patients in the United States, although rates of misdiagnosis may be high. In its severe form, this congenital hypodopaminergic state results in profound hypotonia, developmental impairment, oculogyric crises, dystonia, dysautonomia, hypoglycemia, and premature death. The present study assesses the burden of illness for patients and caregivers by assessment of medical resource utilization (MRU) and quality of life (QOL) measures to enable future health technology assessment activities for emerging therapeutic options.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data from patients’ medical records from the prior two years were examined to estimate burden in terms of direct costs; indirect care burden (including caregiver impact on sleep, health, and vocational opportunities) and QOL were also assessed using the BURQOL-RD, AQoL-6, and Visual Analogue Scale questionnaires.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Data were available for five US cases (three males, two females; age, 2–24 years, median, 5 years). MRU ranged from $6162.73 to $49 043.94 annually per patient. Although the proportion of costs (inpatient and outpatient visits, labs/tests, drugs, devices/durable medical equipment, and speech/physical therapy) varied greatly, the average annual direct cost of healthcare was approximately $25 000. Caregivers described profound care burden and QOL effects, with an average indirect care burden cost assessment of nearly $43 000 yearly. The mean economic burden of AADC deficiency per year was estimated at $68 000.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>MRU and QOL varied considerably by patient. This is attributable to the disease's variable phenotypic severity and differing patient needs. Frequent contact with the healthcare system, however, is a constant for patients with AADC deficiency and their caregivers. Quantifying MRU and QOL for rare genetic diseases is critical for assessing the value of emerging targeted therapies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72232,"journal":{"name":"Annals of the Child Neurology Society","volume":"1 1","pages":"75-81"},"PeriodicalIF":0.0,"publicationDate":"2023-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cns3.20010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48055200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A half-century check-up for child neurology training 半个世纪以来儿童神经学培训的检查
Pub Date : 2023-02-09 DOI: 10.1002/cns3.20015
E. Steve Roach

The ideal approach for child neurology training has become a topic of controversy in recent years, with strong opinions from both sides of the discussion often generating more heat than light. What follows is a dispassionate analysis of our child neurology training requirements. My intent is to facilitate constructive discussion and reframe the questions, not to take sides. We owe it to our trainees and to the children entrusted to us to create the best possible child neurology training.

As a neurologist who still sees adult patients, I am not opposed to adult neurology training for child neurologists. The question is not whether a year of adult neurology training still has value for child neurologists, but whether requiring a full year continues to represent the best use of the residents' time given the major changes in the field in the half century since the basic training requirements were initially established. Similarly, it may be appropriate to discuss the optimal amount of preliminary pediatric training for child neurologists.

The American Board of Psychiatry and Neurology (ABPN) was founded in 1934, and separate training and certification programs for neurologists and psychiatrists began in 1946. In 1959, Sidney Carter became the first child neurologist to serve as an ABPN director. That same year, the ABPN began to include child neurology topics in its certification examination, which at the time consisted of an eight-hour oral examination.2 During the next eight years, a written examination with child neurology topics was introduced, and in 1967, the oral examination was scaled back to four hours, one of which focused on child neurology. In 1969, the ABPN created its “Special Qualification in Child Neurology” category, awarding 106 “grandfather” certificates to individuals who were already focusing on child neurology.2

There have been a number of modifications to the child neurology certification process since it began. The oral examination was eventually reduced to three hours and later replaced entirely with an expanded written examination. Time-limited certification was introduced. The option of dual certification in pediatrics and in neurology remains, although fewer and fewer trainees opt to pursue certification in pediatrics.3 Two infrequently used alternate certification pathways allowing one year of general pediatrics training to be replaced by either internal medicine or pre-approved neuroscience research were approved, of course without the option of certification in general pediatrics. The six-year neurodevelopmental pediatrics track was approved as a separate pathway. Thus, the certification process has not been stagnant, but the requirement for 12 months of clinical adult neurology training has remained intact.

A decade or so ago, the Child Neurology Society's (CNS) leadership and the society's representatives on the Neurology

近年来,儿童神经学训练的理想方法已经成为一个有争议的话题,讨论双方的强烈意见往往产生的热量大于光明。以下是对我们儿童神经学培训要求的客观分析。我的目的是促进建设性的讨论和重新定义问题,而不是偏袒任何一方。我们有责任为我们的学员和孩子们创造最好的儿童神经病学培训。作为一名仍然为成人病人看病的神经科医生,我并不反对对儿童神经科医生进行成人神经学培训。问题不在于一年的成人神经学培训对儿童神经学家是否仍然有价值,而是要求一年的培训是否仍然是对住院医生时间的最佳利用,因为自基本培训要求最初确立以来的半个世纪里,该领域发生了重大变化。同样,讨论儿童神经科医生初步儿科培训的最佳数量可能是合适的。
{"title":"A half-century check-up for child neurology training","authors":"E. Steve Roach","doi":"10.1002/cns3.20015","DOIUrl":"10.1002/cns3.20015","url":null,"abstract":"<p>The ideal approach for child neurology training has become a topic of controversy in recent years, with strong opinions from both sides of the discussion often generating more heat than light. What follows is a dispassionate analysis of our child neurology training requirements. My intent is to facilitate constructive discussion and reframe the questions, not to take sides. We owe it to our trainees and to the children entrusted to us to create the best possible child neurology training.</p><p>As a neurologist who still sees adult patients, I am not opposed to adult neurology training for child neurologists. The question is not whether a year of adult neurology training still has value for child neurologists, but whether requiring a full year continues to represent the best use of the residents' time given the major changes in the field in the half century since the basic training requirements were initially established. Similarly, it may be appropriate to discuss the optimal amount of preliminary pediatric training for child neurologists.</p><p>The American Board of Psychiatry and Neurology (ABPN) was founded in 1934, and separate training and certification programs for neurologists and psychiatrists began in 1946. In 1959, Sidney Carter became the first child neurologist to serve as an ABPN director. That same year, the ABPN began to include child neurology topics in its certification examination, which at the time consisted of an eight-hour oral examination.<span><sup>2</sup></span> During the next eight years, a written examination with child neurology topics was introduced, and in 1967, the oral examination was scaled back to four hours, one of which focused on child neurology. In 1969, the ABPN created its “Special Qualification in Child Neurology” category, awarding 106 “grandfather” certificates to individuals who were already focusing on child neurology.<span><sup>2</sup></span></p><p>There have been a number of modifications to the child neurology certification process since it began. The oral examination was eventually reduced to three hours and later replaced entirely with an expanded written examination. Time-limited certification was introduced. The option of dual certification in pediatrics and in neurology remains, although fewer and fewer trainees opt to pursue certification in pediatrics.<span><sup>3</sup></span> Two infrequently used alternate certification pathways allowing one year of general pediatrics training to be replaced by either internal medicine or pre-approved neuroscience research were approved, of course without the option of certification in general pediatrics. The six-year neurodevelopmental pediatrics track was approved as a separate pathway. Thus, the certification process has not been stagnant, but the requirement for 12 months of clinical adult neurology training has remained intact.</p><p>A decade or so ago, the Child Neurology Society's (CNS) leadership and the society's representatives on the Neurology","PeriodicalId":72232,"journal":{"name":"Annals of the Child Neurology Society","volume":"1 1","pages":"7-12"},"PeriodicalIF":0.0,"publicationDate":"2023-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cns3.20015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43470625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
The NIH Intramural Research Program: Opportunities for training and career development in neuroscience and beyond 美国国立卫生研究院院内研究项目:神经科学及其他领域的培训和职业发展机会
Pub Date : 2023-02-09 DOI: 10.1002/cns3.20012
Nina F. Schor

The National Institutes of Health is renowned for being the largest funder of biomedical research in the world. Although it also houses unique research laboratories and clinics on its campuses around the United States, the National Institutes of Health Intramural Research Program is much less well-known than its extramural enterprise. The Intramural Research Program provides many outstanding opportunities for research-intensive careers and training and includes a vibrant and diverse community of developmental neurobiology and child neurology investigators.

美国国立卫生研究院是世界上最大的生物医学研究资助者。尽管它在美国各地的校园里也有独特的研究实验室和诊所,但美国国立卫生研究院的校内研究项目远不如其校外企业出名。校内研究项目为研究密集型职业和培训提供了许多优秀的机会,包括一个充满活力和多样化的发展神经生物学和儿童神经病学研究人员社区。
{"title":"The NIH Intramural Research Program: Opportunities for training and career development in neuroscience and beyond","authors":"Nina F. Schor","doi":"10.1002/cns3.20012","DOIUrl":"10.1002/cns3.20012","url":null,"abstract":"<p>The National Institutes of Health is renowned for being the largest funder of biomedical research in the world. Although it also houses unique research laboratories and clinics on its campuses around the United States, the National Institutes of Health Intramural Research Program is much less well-known than its extramural enterprise. The Intramural Research Program provides many outstanding opportunities for research-intensive careers and training and includes a vibrant and diverse community of developmental neurobiology and child neurology investigators.</p>","PeriodicalId":72232,"journal":{"name":"Annals of the Child Neurology Society","volume":"1 1","pages":"38-43"},"PeriodicalIF":0.0,"publicationDate":"2023-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cns3.20012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43708101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Demographic characteristics and clinical presentation of infants with infantile epileptic spasms syndrome and their response to therapy: Data from Sri Lanka Infantile Spasms Registry 婴儿癫痫痉挛综合征婴儿的人口学特征、临床表现及其治疗反应:斯里兰卡婴儿痉挛登记处的数据
Pub Date : 2023-02-09 DOI: 10.1002/cns3.20014
Jithangi Wanigasinghe, Gemunu Hewawitharana, Pyara Ratnayake, Saraji Wijesekera, Chathurika Weeraratne, Ashan Jayawickrama, Jayasanka Jayawardena

Objectives

Infantile epileptic spasm syndrome (IESS) is an epileptic encephalopathy with often devastating developmental consequences. Most children with IESS have a known etiology, although differing in proportion by geographical settings. Therefore, registries are useful to understand the characteristics of IESS in different countries. The Sri Lanka Infantile Spasms Registry (SLISR) was established to study the demographics and etiology of infants with IESS and their response to therapy in a resource-limited country.

Methods

Five pediatric neurologists (out of nine) in different parts of the country prospectively recruited children with IESS. The etiology was evaluated using the services available in each setting. Response to treatment for standard (adrenal corticotropic hormone, prednisolone, or vigabatrin) versus nonstandard medications was evaluated at two and six weeks.

Results

Included in the current analysis were 270 children who were registered since 2017. Median age at presentation was 5.36 months (SD 3.6). The mean interval between seizure onset and treatment onset was 1.7 months (SD 1.3). A sizable proportion of the children (61.2%) did not complete the evaluation of etiology. Structural brain abnormality was the most frequently identified etiology in those who were evaluated (38.8%); hypoxic-ischemic injury was the most common antecedent. The majority of the patients (86%) received a recommended standard therapy as the first treatment, with prednisolone being the most frequent choice. By treatment day 14, the first treatment had achieved spasm control in 63.8% and an electro-clinical response in 43.6%. While both standard therapies led to positive outcomes, oral prednisolone produced the best therapeutic response.

Conclusion

We describe the etiologies, treatment choices, and response to first-line medications in a large group of children with IESS from a South Asian country. Although most patients received a recommended first-line therapy (most often prednisolone), a sizable number initially received nonstandard therapy. Our data illustrate the challenges in the management of IESS in a resource-limited environment.

婴儿癫痫性痉挛综合征(IESS)是一种癫痫性脑病,通常具有破坏性的发育后果。大多数患有IESS的儿童都有已知的病因,尽管在地理环境中所占比例有所不同。因此,登记有助于了解不同国家的社会经济状况特征。斯里兰卡婴儿痉挛登记(SLISR)的建立是为了研究在一个资源有限的国家中患有IESS的婴儿的人口统计学和病因学及其对治疗的反应。
{"title":"Demographic characteristics and clinical presentation of infants with infantile epileptic spasms syndrome and their response to therapy: Data from Sri Lanka Infantile Spasms Registry","authors":"Jithangi Wanigasinghe,&nbsp;Gemunu Hewawitharana,&nbsp;Pyara Ratnayake,&nbsp;Saraji Wijesekera,&nbsp;Chathurika Weeraratne,&nbsp;Ashan Jayawickrama,&nbsp;Jayasanka Jayawardena","doi":"10.1002/cns3.20014","DOIUrl":"10.1002/cns3.20014","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Infantile epileptic spasm syndrome (IESS) is an epileptic encephalopathy with often devastating developmental consequences. Most children with IESS have a known etiology, although differing in proportion by geographical settings. Therefore, registries are useful to understand the characteristics of IESS in different countries. The Sri Lanka Infantile Spasms Registry (SLISR) was established to study the demographics and etiology of infants with IESS and their response to therapy in a resource-limited country.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Five pediatric neurologists (out of nine) in different parts of the country prospectively recruited children with IESS. The etiology was evaluated using the services available in each setting. Response to treatment for standard (adrenal corticotropic hormone, prednisolone, or vigabatrin) versus nonstandard medications was evaluated at two and six weeks.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Included in the current analysis were 270 children who were registered since 2017. Median age at presentation was 5.36 months (SD 3.6). The mean interval between seizure onset and treatment onset was 1.7 months (SD 1.3). A sizable proportion of the children (61.2%) did not complete the evaluation of etiology. Structural brain abnormality was the most frequently identified etiology in those who were evaluated (38.8%); hypoxic-ischemic injury was the most common antecedent. The majority of the patients (86%) received a recommended standard therapy as the first treatment, with prednisolone being the most frequent choice. By treatment day 14, the first treatment had achieved spasm control in 63.8% and an electro-clinical response in 43.6%. While both standard therapies led to positive outcomes, oral prednisolone produced the best therapeutic response.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>We describe the etiologies, treatment choices, and response to first-line medications in a large group of children with IESS from a South Asian country. Although most patients received a recommended first-line therapy (most often prednisolone), a sizable number initially received nonstandard therapy. Our data illustrate the challenges in the management of IESS in a resource-limited environment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72232,"journal":{"name":"Annals of the Child Neurology Society","volume":"1 2","pages":"137-143"},"PeriodicalIF":0.0,"publicationDate":"2023-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cns3.20014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47648554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Machine learning and deep learning in medicine and neuroimaging 医学和神经影像学中的机器学习和深度学习
Pub Date : 2023-02-07 DOI: 10.1002/cns3.5
Iván Sánchez Fernández, Jurriaan M. Peters

Artificial intelligence is the science and engineering of machines that can mimic human intelligence. Machine learning is the subfield of artificial intelligence in which computers have the ability to learn and iteratively improve their performance without being explicitly programmed. Deep learning algorithms learn by processing the data with increasing levels of abstraction in each layer. We present a narrative review of the relevant literature with a particular focus on deep learning for image classification and image segmentation in neuroimaging. For the first time in history, computers can automatically perform some clinically relevant tasks at the level, or even above the level, of the relevant medical specialists. A turning point in machine learning occurred in the 2010s as a result of (1) the multiple technical improvements that machine learning has been accumulating over several decades, (2) the exponential increase in computing power, and (3) the wide availability of very large databases with millions of observations and thousands of variables. Machine learning is starting to be successfully applied to several areas of medicine, including predictive analytics, decision support, natural language processing of free-text notes, and automatic interpretation of electrophysiological recordings. Among all the applications of machine learning in medicine, deep learning for computer vision is the one that has enjoyed the greatest success. The emphasis of this review is the application of convolutional neural networks for image classification and for image segmentation in neuroimaging. Machine learning and deep learning are increasingly integrated into the clinical workflow and applied in neuroimaging interpretation. Natural language processing is likely to gain increasing importance in medicine in the near future. Complex decision-making that mimics human thinking with reinforcement learning is still far away on the horizon.

人工智能是能够模仿人类智能的机器的科学和工程。机器学习是人工智能的一个子领域,其中计算机具有学习和迭代提高其性能的能力,而无需明确编程。深度学习算法通过处理数据来学习,并在每一层中增加抽象级别。我们对相关文献进行了叙述性回顾,特别关注神经成像中图像分类和图像分割的深度学习。有史以来第一次,计算机可以自动执行一些与临床相关的任务,达到甚至超过相关医学专家的水平。机器学习的转折点出现在2010年代,这是由于(1)机器学习几十年来积累的多项技术改进,(2)计算能力的指数级增长,以及(3)拥有数百万个观测值和数千个变量的大型数据库的广泛可用性。机器学习开始成功地应用于医学的几个领域,包括预测分析、决策支持、自由文本笔记的自然语言处理和电生理记录的自动解释。在所有机器学习在医学上的应用中,计算机视觉的深度学习是最成功的一个。本文重点介绍了卷积神经网络在图像分类和图像分割中的应用。机器学习和深度学习越来越多地融入临床工作流程,并应用于神经影像学解释。在不久的将来,自然语言处理可能会在医学中变得越来越重要。通过强化学习来模拟人类思维的复杂决策还很遥远。
{"title":"Machine learning and deep learning in medicine and neuroimaging","authors":"Iván Sánchez Fernández,&nbsp;Jurriaan M. Peters","doi":"10.1002/cns3.5","DOIUrl":"10.1002/cns3.5","url":null,"abstract":"<p>Artificial intelligence is the science and engineering of machines that can mimic human intelligence. Machine learning is the subfield of artificial intelligence in which computers have the ability to learn and iteratively improve their performance without being explicitly programmed. Deep learning algorithms learn by processing the data with increasing levels of abstraction in each layer. We present a narrative review of the relevant literature with a particular focus on deep learning for image classification and image segmentation in neuroimaging. For the first time in history, computers can automatically perform some clinically relevant tasks at the level, or even above the level, of the relevant medical specialists. A turning point in machine learning occurred in the 2010s as a result of (1) the multiple technical improvements that machine learning has been accumulating over several decades, (2) the exponential increase in computing power, and (3) the wide availability of very large databases with millions of observations and thousands of variables. Machine learning is starting to be successfully applied to several areas of medicine, including predictive analytics, decision support, natural language processing of free-text notes, and automatic interpretation of electrophysiological recordings. Among all the applications of machine learning in medicine, deep learning for computer vision is the one that has enjoyed the greatest success. The emphasis of this review is the application of convolutional neural networks for image classification and for image segmentation in neuroimaging. Machine learning and deep learning are increasingly integrated into the clinical workflow and applied in neuroimaging interpretation. Natural language processing is likely to gain increasing importance in medicine in the near future. Complex decision-making that mimics human thinking with reinforcement learning is still far away on the horizon.</p>","PeriodicalId":72232,"journal":{"name":"Annals of the Child Neurology Society","volume":"1 2","pages":"102-122"},"PeriodicalIF":0.0,"publicationDate":"2023-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cns3.5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42108768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
期刊
Annals of the Child Neurology Society
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1